Distinguishing indolent from aggressive prostate cancer

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 141-147

  Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROTEOME; TUMOR MARKER;

ARTICLE; CANCER RISK; CARCINOGENESIS; FAMILY HISTORY; GENETIC ASSOCIATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER THERAPY; EARLY CANCER; MALIGNANT TRANSFORMATION; PREDICTION; TUMOR DIFFERENTIATION;

GENOMICS; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84958528312     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_17     Document Type: Article

References (17)

1. Agoulnik IU, Vaid A, Bingman WE 3rd et al (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65: 7959-7967
2. Amundadottir LT, Sulem P, Gudmundsson J et al (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 628-652
3. Cheung PK, Woolcock B, Adomat H (2004) Protein profiling of micro dissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 64: 5929-5933
4. Culig Z, Bartsch G (2006) Androgen axis in prostate cancer. J Cell Biochem 99: 373-381
5. Demichelis F, Rubin MA (2007) TMPRSS2-ETS fusion in prostate cancer: biological and clinical implications. J Clin Pathol 60: 1185-1186
6. Gudmundsson J, Sulem P, Steinhorsdottier V et al (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 potents against type 2 diabetes. Nat Genet 39: 977-983
7. Hara T, Miyazaki J, Araki H et al (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63: 149-153
8. Ishteiwy RA, Ward TM, Dykxhoorn et al (2012) The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration resistant prostate cancer. PLoS One 7(12):e52106
9. Kader AK, Sun J, Isaacs SD et al (2009) Individual and cumulative effect of prostate cancer riskassociated variants on clinicopathologic variables in 5895 prostate cancer patients. Prostate 69: 1195-1205
10. Kote-Jarai Z, Easton DF, Stanford JL et al (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study the PRACTICAL consortium. Cancer Epidemiol Biomark Prev 17: 2052-2061
11. Kreisberg JI, Malik SN, Priboda TJ et al (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236
12. Nanni S, Priolo C, Grasselli A et al (2006) Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 4: 79-82
13. Pin E, Fredolini C, Petricoi E III (2013) The role of proteomics in prostate cancer research: Biomarker discovery and validation. Clin Biochem 46(6): 524-538
14. Puhr M, Hoefer J, Schäfer G et al (2012) Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR- 205. Am J Pathol 181: 2188-2201
15. Saramaki OR, Harjula AE, Martikainen PM (2008) TMPRSS2:ERG fusion identifies a subgroup with favourable prognosis. Clin Cancer Res 14: 3395-3400
16. Xu J, Zheng SL, Isaacs SD (2010) Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA 107: 2136-2140
17. Zheng Y, Xu Y, Ye B et al (2003) Prostate cancer tissue proteomics for biomarker discovery. Cancer 98: 2576-2582